103 related articles for article (PubMed ID: 29197871)
1. Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial.
Roberts MA; Darssan D; Badve SV; Carroll RP; Fahim MA; Haluska BA; Hawley CM; Isbel NM; Marshall MR; Pascoe EM; Pedagogos E; Pilmore HL; Snelling P; Stanton T; Tan KS; Tonkin AM; Vergara LA; Ierino FL
Kidney Blood Press Res; 2017; 42(6):1033-1044. PubMed ID: 29197871
[TBL] [Abstract][Full Text] [Related]
2. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
Gundogdu F; Bozkurt E; Kiziltunc A; Sevimli S; Arslan S; Gurlertop Y; Senocak H; Karakelleoglu S
Echocardiography; 2007 Feb; 24(2):113-7. PubMed ID: 17313541
[TBL] [Abstract][Full Text] [Related]
3. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
[TBL] [Abstract][Full Text] [Related]
4. NT-proBNP and troponin T levels differ after haemodialysis with a low versus high flux membrane.
Laveborn E; Lindmark K; Skagerlind M; Stegmayr B
Int J Artif Organs; 2015 Feb; 38(2):69-75. PubMed ID: 25744196
[TBL] [Abstract][Full Text] [Related]
5. The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial.
Roberts MA; Pilmore HL; Ierino FL; Badve SV; Cass A; Garg AX; Isbel NM; Krum H; Pascoe EM; Perkovic V; Scaria A; Tonkin AM; Vergara LA; Hawley CM;
Am J Kidney Dis; 2016 Jun; 67(6):902-11. PubMed ID: 26717861
[TBL] [Abstract][Full Text] [Related]
6. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
7. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Richards AM; Doughty R; Nicholls MG; MacMahon S; Sharpe N; Murphy J; Espiner EA; Frampton C; Yandle TG;
J Am Coll Cardiol; 2001 Jun; 37(7):1781-7. PubMed ID: 11401111
[TBL] [Abstract][Full Text] [Related]
8. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
9. Troponin I levels in permanent atrial fibrillation-impact of rate control and exercise testing.
Horjen AW; Ulimoen SR; Enger S; Norseth J; Seljeflot I; Arnesen H; Tveit A
BMC Cardiovasc Disord; 2016 May; 16():79. PubMed ID: 27142292
[TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Olsson LG; Swedberg K; Cleland JG; Spark PA; Komajda M; Metra M; Torp-Pedersen C; Remme WJ; Scherhag A; Poole-Wilson P;
Eur J Heart Fail; 2007 Aug; 9(8):795-801. PubMed ID: 17693380
[TBL] [Abstract][Full Text] [Related]
11. Effect of haemodialysis and residual renal function on serum levels of galectin-3, B-type natriuretic peptides and cardiac troponin T.
Roberts MA; Srivastava PM; Hare DL; Ierino FL
Nephrology (Carlton); 2018 Dec; 23(12):1131-1138. PubMed ID: 29028161
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker.
Kojima M; Sato K; Kimura G; Ueda R; Dohi Y
J Cardiovasc Pharmacol; 2007 Apr; 49(4):191-6. PubMed ID: 17438403
[TBL] [Abstract][Full Text] [Related]
13. Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol.
Arslan S; Erol MK; Bozkurt E; Acikel M; Gundogdu F; Atesal S; Senocak H
Int J Cardiovasc Imaging; 2007 Oct; 23(5):549-55. PubMed ID: 17171429
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol.
Kaya MG; Sarli B; Akpek M; Kaya EG; Yarlioglues M; Topsakal R; Lam YY
Cardiol J; 2014; 21(4):434-41. PubMed ID: 24142686
[TBL] [Abstract][Full Text] [Related]
15. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
Fragasso G; Spoladore R; Maranta F; Corti A; Lattuada G; Colombo B; Locatelli M; Salerno A; Calori G; Briceno L; Alfieri AB; Perseghin G; Margonato A
J Cardiovasc Med (Hagerstown); 2013 Jan; 14(1):49-56. PubMed ID: 23018486
[TBL] [Abstract][Full Text] [Related]
16. The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
Khand AU; Chew PG; Douglas H; Jones J; Jan A; Cleland JG
Cardiology; 2015; 130(3):153-8. PubMed ID: 25660493
[TBL] [Abstract][Full Text] [Related]
17. Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure.
Susa T; Kobayashi S; Tanaka T; Murakami W; Akashi S; Kunitsugu I; Okuda S; Doi M; Wada Y; Nao T; Yamada J; Ueyama T; Okamura T; Yano M; Matsuzaki M
Circ J; 2012; 76(1):117-26. PubMed ID: 22008315
[TBL] [Abstract][Full Text] [Related]
18. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
Frantz RP; Olson LJ; Grill D; Moualla SK; Nelson SM; Nobrega TP; Hanna RD; Backes RJ; Mookadam F; Heublein D; Bailey KR; Burnett JC
Am Heart J; 2005 Mar; 149(3):541-7. PubMed ID: 15864245
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Anker SD; Amann-Zalan I; Hoersch S; Katus HA
Circulation; 2004 Sep; 110(13):1780-6. PubMed ID: 15381643
[TBL] [Abstract][Full Text] [Related]
20. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
Fujimura M; Akaike M; Iwase T; Yoshida S; Sumitomo Y; Yagi S; Ikeda Y; Hashizume S; Aihara K; Nishiuchi T; Yasumura Y; Matsumoto T
Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
